I submitted two sealed samples of Generopharm oils for independent laboratory analysis through JanoShik Analytical in October 2025. The goal was to confirm label accuracy and verify overall quality and consistency. Testing was performed using full qualitative and quantitative AAS analysis via HPLC.

Testing was ordered on October 9, 2025, the samples were received on October 20, 2025, and the analysis was conducted on October 21, 2025.

Sample 1: Genero Test C200
Label claim: 200 mg/mL Testosterone Cypionate
Laboratory result: 189.75 mg/mL
Deviation from label: –5.1%

Interpretation:
This concentration falls well within the United States Pharmacopeia (USP) potency tolerance of plus or minus 10 percent for sterile injectable preparations. Both pharmaceutical-grade and compounding-grade testosterone cypionate are considered compliant within the 180 to 220 mg/mL range. The product shows proper ester identification and formulation consistency.

Sample 2: Genero Test E250
Label claim: 250 mg/mL Testosterone Enanthate
Laboratory result: 241.80 mg/mL
Deviation from label: –3.3%

Interpretation:
This result also falls well within the USP specification range (225 to 275 mg/mL). The chromatographic profile demonstrated a single testosterone ester peak with no indication of impurities or dilution, suggesting correct formulation and concentration.

Conclusion:
Both Generopharm samples tested within pharmaceutical tolerance for potency and purity. A deviation between 3 and 5 percent is normal and acceptable for both FDA-approved and 503A/503B compounding pharmacy products. These results indicate accurate concentration, stable ester integrity, and legitimate formulation. No signs of underdosing or contamination were observed.